anti-Solute Carrier Family 16, Member 1 (Monocarboxylic Acid Transporter 1) (SLC16A1) Antikörper

Human Solute Carrier Family 16, Member 1 (Monocarboxylic Acid Transporter 1) (SLC16A1) Interaktionspartner

1. High MCT-1 (zeige CMA1 Antikörper) expression is associated with clear cell renal cell carcinoma (zeige MOK Antikörper).

2. Metabolism-dependent clonal growth of HCT15 colorectal cancer cells was induced by Nrf2 (zeige GABPA Antikörper)-dependent activation of MCT1 (zeige CMA1 Antikörper)-driven lactate exchange.

3. Using in vitro models, we demonstrate that tumor-excreted branched-chain amino acid (BCKA)s can be taken up and re-aminated to BCAAs by tumor-associated macrophages. Our data further suggest that the anti-proliferative effects of MCT1 (zeige CMA1 Antikörper) knockdown observed by others might be related to the blocked excretion of BCKAs.

4. Study demonstrated that the high mRNA level of both MCT1 (zeige CMA1 Antikörper) and GLUT1 (zeige SLC2A1 Antikörper) correlated with poor prognosis, high- Fuhrman grade clear-cell renal cell carcinoma (zeige MOK Antikörper) and metabolic reprogramming.

5. Hypoxia-induced MCT1 (zeige CMA1 Antikörper) supports glioblastoma glycolytic phenotype, being responsible for lactate efflux and an important mediator of cell survival and aggressiveness

6. our finding that the expression of MCT1 (zeige CMA1 Antikörper) and MCT4 (zeige SLC16A4 Antikörper) is reduced in mutant IDH1 (zeige IDH1 Antikörper) gliomas highlights the unusual metabolic reprogramming that occurs in mutant IDH1 (zeige IDH1 Antikörper) tumors and has important implications for our understanding of these tumors and their treatment

7. MCT1 (zeige CMA1 Antikörper) expression, independent of transporter activity, is required for growth factor-induced tumor cell motility.

8. TOMM20 (zeige TOMM20 Antikörper), MCT1 (zeige CMA1 Antikörper), and MCT4 (zeige SLC16A4 Antikörper) expression was significantly different in Hodgkin and Reed Sternberg (HRS) cells. HRS have high expression of MCT1 (zeige CMA1 Antikörper), while tumor associated macrophages have absent MCT1 (zeige CMA1 Antikörper) expression. Tumor-infiltrating lymphocytes have absent MCT1 (zeige CMA1 Antikörper) expression. Reactive lymph nodes in contrast to cHL (zeige CHRDL1 Antikörper) tumors had low TOMM20 (zeige TOMM20 Antikörper), MCT1 (zeige CMA1 Antikörper), and MCT4 (zeige SLC16A4 Antikörper) expression in lymphocytes and macrophages.

9. TOMM20 (zeige TOMM20 Antikörper) and MCT1 (zeige CMA1 Antikörper) were highly expressed in diffuse large B-cell lymphoma lymphocytes, indicating an OXPHOS phenotype, whereas non-neoplastic lymphocytes in the control samples did not express these markers.

10. MCT1 (zeige CMA1 Antikörper) inhibitor AZD3965 increased MCT4 (zeige SLC16A4 Antikörper)-dependent accumulation of intracellular lactate, inhibiting monocarboxylate influx and efflux.

Zebrafish Solute Carrier Family 16, Member 1 (Monocarboxylic Acid Transporter 1) (SLC16A1) Interaktionspartner

1. Data indicate that monocarboxylate transporters (MCTs1 (zeige MCTS1 Antikörper)-4) were all found to be expressed in brains of embryos, and were localized in both neurons and astrocyte.

Horse (Equine) Solute Carrier Family 16, Member 1 (Monocarboxylic Acid Transporter 1) (SLC16A1) Interaktionspartner

1. The expression of monocarboxylic acid transporter 1 (MCT1 (zeige MCTS1 Antikörper)), MCT2 (zeige SLC16A7 Antikörper), and CD147 in 3 horse breeds with different atheletic demands is reported.[MCT1 (zeige MCTS1 Antikörper); MCT2 (zeige SLC16A7 Antikörper)]

2. Results indicated that a single IET resulted in transient increases in MCT1 (zeige MCTS1 Antikörper) and MCT4 (zeige SLC16A3 Antikörper) mRNA expression and protein content in untrained and trained horses.

3. The coding sequence of MCT1 (zeige MCTS1 Antikörper), MCT4 (zeige SLC16A3 Antikörper), and CD147 in healthy horses, and the incidence of polymorphisms of these proteins in horses with excercise-induced myopathy are reported.

4. MCT1 (zeige MCTS1 Antikörper) protein content in GMM samples obtained when the horses were 24 months old was significantly higher than at 2 months of age. However, MCT4 (zeige SLC16A3 Antikörper) protein content remained unchanged throughout the study period.

Mouse (Murine) Solute Carrier Family 16, Member 1 (Monocarboxylic Acid Transporter 1) (SLC16A1) Interaktionspartner

1. Silencing or genetic deletion of MCT1 (zeige MCTS1 Antikörper) in vivo inhibited migration, invasion, and spontaneous metastasis.

2. It was concluded that both MCT1 (zeige MCTS1 Antikörper) and CAII (zeige CA2 Antikörper) are involved in the homeostatic control of pH in skeletal muscle, both at rest and at the onset of exercise. The improved muscle function and resistance to fatigue in MCT1 (zeige MCTS1 Antikörper)(+/-) mice remain unexplained.

3. Exercise-induced changes in tumour LDH-B (zeige LDHB Antikörper) and MCT1 (zeige MCTS1 Antikörper) expression are modulated by oestrogen-related receptor alpha in breast cancer-bearing BALB/c mice

4. Chronic lactate administration after exercise increases MCT1 (zeige MCTS1 Antikörper) protein expression, which can be involved in the regulation of the observed increase in muscle glycogen (zeige GYS1 Antikörper) storage after exercise training.

5. This study showed that mouse MCT1 (zeige MCTS1 Antikörper), MCT2 (zeige SLC16A7 Antikörper), and MCT4 (zeige SLC16A3 Antikörper) are expressed in the PNS. While DRG neurons express MCT1 (zeige MCTS1 Antikörper), myelinating Schwann cells.

6. These data for the first time demonstrate that MCT1 (zeige MCTS1 Antikörper) is critical for regeneration of both sensory and motor axons in mice following sciatic nerve crush

7. in Parkinson's disease, the levels of MCT1 (zeige MCTS1 Antikörper), MCT2 (zeige SLC16A7 Antikörper) and GLUT1 (zeige SLC2A1 Antikörper) is not changed following dopaminergic neurodegeneration

8. results suggest that a reduction in mitochondria is a result, rather than the cause, of the metabolic deficiency observed in Basigin-null mice, and likely occurs because of reduced metabolic activity in the absence of MCT1 (zeige MCTS1 Antikörper) expression.

9. miR (zeige MLXIP Antikörper)-29a, miR (zeige MLXIP Antikörper)-29b selectively target MCT1 (zeige MCTS1 Antikörper) 3'UTR (zeige UTS2R Antikörper) ; the miR (zeige MLXIP Antikörper)-29 isoforms are highly expressed in islets and contribute to silencing Mct1 (zeige MCTS1 Antikörper) in beta cells; miR (zeige MLXIP Antikörper)-29 isoforms contribute to beta-cell-specific silencing of the MCT1 (zeige MCTS1 Antikörper) transporter and may affect insulin (zeige INS Antikörper) release

10. monocarboxylate transporter 1 (MCT1), is highly enriched within oligodendroglia and disruption of this transporter produces axon damage and neuron loss in animal and cell culture models; in addition, this same transporter is reduced in patients with, and in mouse models of, amyotrophic lateral sclerosis, suggesting a role for oligodendroglial MCT1 (zeige MCTS1 Antikörper) in pathogenesis

Cow (Bovine) Solute Carrier Family 16, Member 1 (Monocarboxylic Acid Transporter 1) (SLC16A1) Interaktionspartner

1. This study confirmed age-dependent changes of MCT1 (zeige MCTS1 Antikörper) expression in the rumen epithelium of newborn calves and showed that its expression might be affected by liquid feed type.

2. These findings show that MCT 1 (zeige MCTS1 Antikörper) increases with the development of rumen function and also in adult animals MCT 1 (zeige MCTS1 Antikörper) may change with the feeding.

3. The expression and distribution of monocarboxylate transporter 1 along the gastrointestinal tract of calves suggest it may play a role in transport of short chain fatty acids and their metabolites.

4. The results show that monocarboxylate transporter 1 (MCT1) is a major route for short chain fatty acids (SCFA) efflux across the basolateral membrane of bovine large intestine and that it could play a role in the regulation of intracellular pH.